News
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...
WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...
Viking is developing what might be a game-changing medication in the segment.
Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.
Zacks.com on MSN1d
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock DownEli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...
Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback